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Abstract
HIV infection has been associated with diastolic heart failure and atrial fibrillation. The purpose of this study is to
determine whether HIV infection is associated with differences in left ventricular mass (LVM), left ventricular
end-diastolic volume (LVEDV), and left atrial volume (LAV) indexed to body surface area (left ventricular mass
index, left ventricular end-diastolic volume index [LVEDVI], and left atrial volume index [LAVI], respectively).
Cross-sectional study of 721 men [425 HIV-infected (HIV+), 296 HIV-uninfected (HIV-) enrolled in the car-
diovascular substudy of the Multicenter AIDS Cohort Study (MACS). Participants underwent cardiac computed
tomography imaging. A blinded reader measured LVM, LVEDV, and LAV. We used multivariable linear re-
gression models to evaluate whether LVEDVI, left ventricular mass index (LVMI), and LAVI differed by HIV
serostatus, adjusting for demographics and cardiovascular disease risk factors. LVMI was significantly greater in
HIV+ compared with HIV- men, with adjusted difference of 2.65 g/m2 (95% confidence interval 0.53–4.77,
p < .001). Left ventricular end-diastolic index and LAVI did not differ significantly between the two groups. HIV-
related factors (nadir CD4 count, clinical AIDS diagnosis, cumulative antiretroviral therapy use, and cumulative
protease inhibitor use) were not significantly associated with LVMI, LVEDVI, or LAVI. LVM was significantly
higher in HIV+ than HIV- men, which may contribute to the observed increased risk for diastolic heart failure
associated with HIV infection. Although HIV infection has been associated with an increased risk for atrial
fibrillation, we did not find any difference in LAV by HIV serostatus.
Keywords: AIDS, HIV, cardiomyopathy, heart failure, diastolic, tomography, X-ray computed tomography,
atrial fibrillation
Introduction
S ince the advent of highly active antiretroviral therapy(HAART) in 1996, life expectancy of persons living with
HIV (PLWH) has increased dramatically. As per CDC esti-
mates, in 2015, roughly half of PLWH were older than 50
years.1 With increased life expectancy, PLWH are prone to
chronic health conditions, particularly cardiac diseases.
PLWH have increased risk of cardiovascular events,2 heart
failure,3,4 and atrial fibrillation,5 however, the underlying
mechanisms are not fully understood. In the general popu-
lation, alterations in cardiac structure underlie many cardiac
syndromes. In particular, left ventricular hypertrophy is a
predictor of cardiovascular events (sudden cardiac death,
ventricular arrhythmias) and heart failure6–8 and increased left
atrial volume (LAV) is associated with atrial fibrillation9 and
heart failure.10
Some studies have shown alterations in cardiac structure in
PLWH, particularly with regard to increased left ventricular
mass (LVM).11 More evidence is needed, however, to under-
stand the impact of long-term HIV infection on cardiac struc-
ture. In this study, we compare body surface area (BSA)-
indexed LVM, left ventricular end-diastolic volume (LVEDV),
and LAV using contrast-enhanced cardiac computed tomog-
raphy (CT) in HIV-infected (HIV+) and uninfected (HIV-) men
enrolled in the Multicenter AIDS Cohort Study (MACS).
1Los Angeles Biomedical Research Institute, Torrance, California.
2Department of Epidemiology, Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland.
3Department of Infectious Diseases and Microbiology, University of Pittsburgh Graduate School of Public Health, Pittsburgh, Pennsylvania.
4Feinberg School of Medicine, Division of Infectious Diseases, Northwestern University, Chicago, Illinois.
5Division of Cardiology, Johns Hopkins School of Medicine, Baltimore, Maryland.
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Materials and Methods
Study population
The study population consisted of HIV+ and HIV- men
enrolled in the MACS who underwent CT coronary angiogra-
phy as part of an MACS Cardiovascular Ancillary Study. De-
tailed description of MACS and the subset of participants who
had cardiac CT scans has been reported previously.12,13 Briefly,
MACS is an ongoing cohort study of the natural and treated
histories of HIV-1 infection in homosexual and bisexual men,
conducted in four U.S. communities in Baltimore/Washington,
DC, Chicago, Pittsburgh, and Los Angeles. The study had
initial enrollment in 1984–1985, with additional enrollments in
1987–1991 and 2001–2003. The cohort has recruited both
HIV+ and HIV- men who attend semiannual research visits
during which they undergo standardized interviews and phys-
ical examinations, and blood and urine samples are collected.
Inclusion criteria for this MACS Cardiovascular Ancillary
Study are as follows: being an active MACS participant (with
oversampling of HIV-infected men), age 40 to 70 years,
weight less than 300 pounds, and no history of cardiac sur-
gery or percutaneous coronary intervention, as these proce-
dures would interfere with the measurement of coronary
atherosclerosis. Exclusion criteria for CT coronary angio-
graphy included the following: atrial fibrillation, chronic
kidney disease (estimated glomerular filtration rate
<60 mL/min/m2 within 30 days of the CT scan), or a history
of intravenous contrast allergy. The study was approved by
the institutional review boards of all participating sites, and
all participants signed informed consent. All eligible partic-
ipants who were enrolled completed cardiac CT scanning
between January 2010 and June 2013.
Imaging and laboratory
The CT scanning methods and analytic approach were
previously described.14 Briefly, noncontrast CT and coronary
CT angiography were performed using a 64-slice multi-
detector scanner at three centers and a 320-slice scanner at the
fourth center.
Men were pretreated with beta-blockers or calcium channel
blockers as needed to slow the heart rate and with sublingual
nitroglycerin unless contraindicated. Quantitative data analy-
ses were performed using automated methods on a workstation
and software (AW 4.6; GE Medical Systems, Waukesha, WI)
that used a Hounsfield unit-based endocardial border detection
technique. Images were reconstructed with a 1.25 mm slice
thickness. The mid-diastolic phases were chosen for mea-
surements of left atrium (LA) and left ventricle (LV) volume
and LV mass. The LA appendage and pulmonary veins were
not included in the LA volume measurement. LVM was also
simultaneously calculated automatically. The user acquiring
the measurements was blind to participant characteristics and
HIV serostatus. Use of contrast CT for measurement of
chamber size and LVM has been validated in other studies.15–17
Clinical data from the MACS semiannual research visit
most proximal to the CT scan were used. Laboratory as-
sessment included serum creatinine levels within 30 days of
CT angiography, serum glucose levels, total and high-density
lipoprotein (HDL) cholesterol and triglyceride levels, and
low-density lipoprotein (LDL) levels calculated using the
Friedewald equation or measured directly if nonfasting or
if triglycerides >400 mg/dL. HIV-related characteristics in-
cluded plasma HIV RNA levels and CD4 T cell counts
(cells/lL; current and nadir), years on antiretroviral therapy,
and history of clinical AIDS. Ethnicity and smoking status were
self-reported. Hypertension was defined as blood pressure
>140/90 mmHg or the use of antihypertensive agents with a
self-reported history of hypertension. Diabetes was defined as
fasting plasma glucose ‡126 mg/dL or use of medications
prescribed for diabetes with a self-reported history of diabetes.
Statistical analyses
Demographic and clinical characteristics were determined
at the time of baseline cardiac CT visit and compared by HIV
serostatus. Wilcoxon rank-sum test and chi-squared test were
used for continuous and categorical variables, respectively.
Chamber size measurements were indexed to BSA to generate
left ventricular mass index (LVMI), left ventricular end-
diastolic index (LVEDI), and left atrial volume index (LAVI),
which were used for statistical analyses. We conducted two
analyses to assess the relationships between HIV infection and
LVMI, left ventricular end-diastolic volume index (LVEDVI),
and LAVI.
In the first analysis, we used linear regression to evaluate
whether the levels of the three indices obtained from the
baseline cardiac CT scan differed by HIV serostatus. We con-
structed separate models for each outcome. We first reported
results from a univariable model that included HIV serostatus
as the exposure. Then, in a minimally adjusted model, we
accounted for the differences in demographic characteristics
between HIV+ and HIV- men by including age, race (African
American, Hispanic/other vs. white), MACS center, and en-
rollment cohort (pre/post 2001). Finally, we accounted for
potential confounding due to cardiovascular disease (CVD) risk
factors using a model that additionally adjusted for systolic
and diastolic blood pressure (BP), use of antihypertensive
medication, fasting glucose, use of diabetic medication, total
and HDL cholesterol levels, use of lipid-lowering medication,
and tobacco smoking (never, former, and current).
We also conducted analysis only among HIV+ men to in-
vestigate the relationships between the baseline levels of the
three outcomes and HIV-related factors (detectable viral load,
defined as HIV viral load >50 copies/mL, the most recent CD4
cell count, nadir CD4 cell count, prior clinically defined AIDS
diagnosis, and the duration of HAART use and protease in-
hibitor [PI] use). We added each of the HIV-related factors to a
separate model that simultaneously accounted for demo-
graphic and CVD risk factors as described previously.
In the multivariable regression analyses, data were missing
for CVD risk factors (blood pressure: N = 2; antihypertensive
medication: N = 6; fasting glucose: N= 9; diabetic medica-
tion: N = 15; cholesterol levels: N= 2; cholesterol-lowering
medication: N = 17; tobacco smoking: N = 6). To account for
missing values in these covariates, we conducted multiple
imputations using the Markov-chain Monte Carlo method by
assuming multivariable normality.18 Ten multiply imputed
data sets were obtained. Model coefficients were estimated in
each imputed data set and then pooled using the PROC
MIANALYZE procedure in SAS. All statistical analyses
were conducted using SAS, version 9.4 (SAS Institute, North
Carolina). p Values below .05 were considered statistically
significant.
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Results
Participant characteristics
Among the 759 participants who underwent contrast-
enhanced CT scanning, 721 had scans suitable for LVMI,
LVEDVI, and LAVI; of those, 425 were HIV+ and 296 HIV-.
HIV+men were younger (mean 51 years vs. 54 years, p< .001)
and more likely to be non-white (68% vs. 49% p< .001)
(Table 1). HIV+ men had lower HDL (45.3 mg/dL vs.
51.1 mg/dL) and LDL cholesterol (106 mg/dL vs. 116 mg/dL)
and higher triglyceride levels (128.5 mg/dL vs. 107.5 mg/dL).
Both groups had similar prevalence of hypertension and dia-
betes. HIV+ men were less likely to drink alcohol and had
a lower body mass index. Median cumulative tobacco use
Table 1. Baseline Characteristics by HIV Serostatus
Characteristics HIV-infected (N= 425) HIV-uninfected (N= 296) p
Age, median (IQR), years 51 (47–57) 54 (50–61) <.001
Race, n (%)
White, non-Hispanic 210 (49) 201 (68) <.001
Black, non-Hispanic 148 (35) 72 (24)
Hispanic/other 67 (16) 23 (8)
Center, n (%)
Baltimore 107 (25) 94 (32) .094
Chicago 121 (29) 67 (23)
Pittsburgh 72 (17) 58 (20)
LA 125 (29) 77 (26)
Cohort, n (%)
Pre-2001 194 (46) 190 (64) <.001
2001+ 231 (54) 106 (36)
Hypertension, n (%) 178 (44) 116 (42) .54
Systolic blood pressure, median (IQR), mmHg 125 (115–136) 128 (118–137) .10
Diastolic blood pressure, median (IQR), mmHg 77 (72–84) 78 (71–83) .70
Hypertension medication use, n (%) 132 (31) 86 (30) .65
Diabetes, n (%) 45 (11) 20 (7) .086
Glucose level, median (IQR), mg/dL 97 (90–107) 96.5 (88.5–103) .032
Diabetes medication use, n (%) 35 (8) 16 (6) .15
Total cholesterol, median (IQR), mg/dL 187 (163–214) 195 (168–220) .016
LDL cholesterol, median (IQR), mg/dL 106 (84–134) 116 (94–139) .001
HDL cholesterol, median (IQR), mg/dL 45 (39–55) 51 (42–61) <.001
Triglyceride, median (IQR), mg/dL 129 (89–197) 108 (74–147) <.001
Lipid-lowering medication, n (%) 137 (33) 89 (31) .57
BMI, median (IQR), kg/m2 25.6 (23.1–28.3) 26.5 (24.0–29.7) .002
Tobacco use, n (%)
Never 109 (26) 67 (23) .011
Former 187 (44) 161 (55)
Current 127 (30) 64 (22)
Cumulative tobacco use, median (IQR), pack-years 5.9 (0–22.2) 4.5 (0–23.1) .59
Alcohol use, n (%)
None 95 (23) 39 (13) <.001
1 to 3 drinks/week 227 (54) 140 (48)
4 to 13 drinks/week 79 (19) 83 (28)
More than 13 drinks/week 22 (5) 30 (10)
HIV clinical characteristics
Undetectable HIV RNA copies, n (%) 342 (81)
HIV RNA level, median (IQR), copies/mL 993 (143–26,350)
Current CD4+ T cell count, median (IQR), cells/mL 599 (437–766)
Nadir CD4+ T cell count, median (IQR), cells/mL 299 (187–432)
Current HAART use, n (%) 378 (89)
Cumulative HAART exposure, median (IQR), years 9.2 (6.2–12.2)
Current PI use, n (%) 199 (47)
Cumulative PI exposure, median (IQR), years 4.8 (0.3–9.2)
Current NNRTI use, n (%) 202 (48)
Cumulative NNRTI exposure, median (IQR), years 3.9 (0.6–7.9)
Current NRTI use, n (%) 375 (89)
Cumulative NRTI exposure, median (IQR), years 11.4 (7.6–14.2)
History of AIDS, n (%) 47 (11)
BMI, body mass index; HAART, highly active antiretroviral therapy; HDL, high-density lipoprotein; IQR, interquartile range; LA, Los
Angeles; LDL, low-density lipoprotein; NNRTI, non-nucleoside reverse transcriptase inhibitors; NRTI, nucleoside analog reverse-
transcriptase inhibitors; PI, protease inhibitor.
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between the two groups was similar; however, HIV+men were
more likely to be current smokers. Among the HIV+ men,
average current CD4+ count was 599 cells/lL, 81% had un-
detectable viral load, 91% were currently on HAART, and
13% had a history of AIDS (Table 1).
Cardiac CT findings
There were 721 participants with scans suitable for mea-
surement and included in the analysis. To address whether
LVMI, LVEDVI, and LAVI differed by serotype, the three
models described above were constructed for each variable of
interest as shown in Tables 2–4, respectively. For each var-
iable of interest (LVMI, LVEDI, LAVI), model 1 reports
unadjusted values by serotype, model 2 adjusts for demo-
graphic variables (minimally adjusted model), and model 3 is
a fully adjusted model, adjusting for both demographic var-
iables and CVD risk factors.
In all three models, HIV+ men had greater LVMI than
HIV- men, with a mean difference of 2.90 g/m2 (54.48 vs.
Table 3. Association of HIV Serostatus with LVEDVI: Unadjusted Model (Model 1), Minimally
Adjusted Model (Model 2), Fully Adjusted Model (Model 3)
Variables
Model 1 Model 2 Model 3
Mean difference in
LV volume (95% CI) p
Mean difference in
LV volume (95% CI) p
Mean difference in
LV volume (95% CI) p
HIV infection 1.85 (-0.41 to 4.10) .11 0.25 (-1.99 to 2.49) .83 1.13 (-1.14 to 3.39) .33
Age, per 10 years -3.41 (-5.35 to -1.47) <.001 -2.85 (-4.86 to -0.84) .01
African American (ref =white) 0.15 (-2.70 to 3.00) .92 0.21 (-2.75 to 3.17) .89
Hispanic/other (ref =white) 3.13 (-0.75 to 7.01) .11 3.63 (-0.28 to 7.54) .07
2001+ cohort (ref = pre-2001) 2.24 (-0.63 to 5.11) .13 2.20 (-0.68 to 5.09) .13
Systolic blood pressure,
per 10 mmHg
0.48 (-0.56 to 1.52) .365
Diastolic blood pressure,
per 10 mmHg
-1.87 (-3.39 to -0.36) .02
On antihypertensive medication -1.59 (-4.06 to 0.88) .21
Fasting glucose, per 10 mg/dL -0.39 (-0.89 to 0.12) .14
On diabetes medication 0.02 (-4.66 to 4.69) .00
Total cholesterol, per 10 mg/dL -0.07 (-0.36 to 0.23) .66
HDL cholesterol, per 10 mg/dL 0.98 (0.23 to 1.74) .01
On lipid-lowering medication -2.96 (-5.43 to -0.48) .02
Former smoker (ref = never) -1.58 (-4.24 to 1.08) .24
Current smoker (ref = never) -2.42 (-5.53 to 0.68) .13
Also includes adjustment for MACS clinic site.
LVEDV, left ventricular end-diastolic volume index.
Table 2. Association of HIV Serostatus with LVMI: Unadjusted Model (Model 1),
Minimally Adjusted Model (Model 2), Fully Adjusted Model (Model 3)
Variables
Model 1 Model 2 Model 3
Mean difference in
LV mass (95% CI) p
Mean difference in
LV mass (95% CI) p
Mean difference in
LV mass (95% CI) p
HIV infection 2.93 (0.78 to 5.07) .01 2.66 (0.48 to 4.84) .02 2.65 (0.53 to 4.77) .01
Age, per 10 years -1.34 (-3.23 to 0.56) .17 -2.99 (-4.87 to -1.11) .00
African American (ref =white) 4.02 (1.24 to 6.79) .01 2.97 (0.20 to 5.74) .04
Hispanic/other (ref =white) -1.36 (-5.14 to 2.42) .48 -0.39 (-4.05 to 3.26) .83
2001+ cohort (ref = pre-2001) -0.66 (-3.45 to 2.14) .64 -1.61 (-4.31 to 1.09) .24
Systolic blood pressure,
per 10 mmHg
3.41 (2.45 to 4.38) <.001
Diastolic blood pressure,
per 10 mmHg
-0.82 (-2.23 to 0.60) .26
On antihypertensive medication 1.03 (-1.28 to 3.34) .38
Fasting glucose, per 10 mg/dL 0.14 (-0.33 to 0.62) .55
On diabetes medication 2.07 (-2.30 to 6.44) .35
Total cholesterol, per 10 mg/dL -0.28 (-0.56 to -0.00) .05
HDL cholesterol, per 10 mg/dL 0.02 (-0.68 to 0.73) .95
On lipid-lowering medication 1.03 (-1.30 to 3.36) .38
Former smoker (ref = never) 0.36 (-2.13 to 2.85) .78
Current smoker (ref = never) 3.16 (0.25 to 6.06) .03
Also includes adjustment for MACS clinic site.
CI, confidence interval; LV, left ventricle; LVMI, left ventricular mass index; MACS, Multicenter Aids Cohort Study.
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51.58, p< .001) in the fully adjusted model. In model 3, our
study also demonstrated well-known associations. In partic-
ular, higher systolic BP, African American race, and smoking
were positively associated with LVMI, and increasing age
was inversely associated with LVMI.
The adjusted difference in mean LVEDV index between the
two groups in the fully adjusted model was 0.97 mL/m2 and
not statistically significant (59.47 mL/m2 vs. 58.50 mL/m2 in
HIV+ vs. HIV-, respectively, p= .42) (Table 3). Similarly,
there was no difference in mean LAVI (mL/m2) between
HIV+ and HIV- men (46.09 mL/m2 vs. 45.39 mL/m2, re-
spectively, p= .43) (Table 4).
Association of HIV clinical factors with chamber size
Among HIV+ men, there were no associations between
cardiac chamber size and clinical HIV factors measured.
Specifically, detectable viral load (defined as HIV viral load
>50 copies/mL), the most recent CD4 cell count, nadir CD4
cell count, prior clinically defined AIDS diagnosis, and the
duration of HAART use and PI use were not related to LVMI,
LVEDVI, and LAVI (Table 5).
Discussion
Since the advent of HAART, there has been a well-
described evolution of the cardiac manifestations of HIV
infection, otherwise termed HIV-associated cardiomyopathy
(HIVAC).19 In pre-HAART era, HIVAC was characterized
as left-ventricular dilation with symptomatic systolic dys-
function.20 In the current era of widespread HAART use,
diastolic dysfunction is the hallmark of HIVAC.21 The
mechanism behind this shift in phenotype is not fully un-
derstood, although the antiretroviral medications themselves
have been implicated.20,22
In the current study, HIV+men had greater LVMI compared
with HIV- men. These results add to a growing body of evi-
dence demonstrating increased LVM in PLWH, and represent
Table 4. Association of HIV Serostatus with LAVI: Unadjusted Model (Model 1), Minimally
Adjusted Model (Model 2), Fully Adjusted Model (Model 3)
Variables
Model 1 Model 2 Model 3
Mean difference in
LA volume (95% CI) p
Mean difference in
LA volume (95% CI) p
Mean difference in
LA volume (95% CI) p
HIV infection -0.06 (-1.74 to 1.61) .94 0.68 (-0.98 to 2.34) .42 1.03 (-0.66 to 2.72) .23
Age, per 10 years 3.10 (1.66 to 4.54) <.001 3.30 (1.80 to 4.80) <.001
African American (ref =white) -1.47 (-3.58 to 0.64) .17 -2.16 (-4.37 to 0.05) .06
Hispanic/other (ref =white) 2.56 (-0.31 to 5.44) .08 2.45 (-0.47 to 5.37) .10
2001+ cohort (ref = pre-2001) 2.87 (0.74 to 5.00) .01 2.91 (0.76 to 5.07) .01
Systolic blood pressure,
per 10 mmHg
0.37 (-0.41 to 1.15) .35
Diastolic blood pressure,
per 10 mmHg
0.01 (-1.12 to 1.15) .98
On antihypertensive medication 0.66 (-1.20 to 2.52) .49
Fasting glucose, per 10 mg/dL 0.09 (-0.29 to 0.47) .64
On diabetes medication 1.26 (-2.28 to 4.80) .48
Total cholesterol, per 10 mg/dL -0.08 (-0.30 to 0.15) .50
HDL, per 10 mg/dL 0.49 (-0.07 to 1.05) .09
On lipid-lowering medication -2.98 (-4.83 to -1.14) .00
Former smoker (ref = never) -1.69 (-3.68 to 0.30) .10
Current smoker (ref = never) -1.83 (-4.15 to 0.50) .12
Also includes adjustment for MACS clinic site.
LAVI, left atrial volume index.
Table 5. Association of HIV Clinical Factors with LVMI, LVEDVI, LAVI Among
HIV-Infected Men: Fully Adjusted Model (n= 425)
Variables
Mean difference
in LVMI (95% CI) p
Mean difference in
LVEDVI (95% CI) p
Mean difference in
LAVI (95% CI) p
Detectable VL, VL >50 copies/mL 1.86 (-2.08 to 5.81) .35 3.64 (-0.13 to 7.42) .06 1.32 (-1.54 to 4.17) .37
Most recent CD4+ T cell count,
per 100 cells/mm3
-0.33 (-0.89 to 0.23) .24 -0.50 (-1.03 to 0.04) .07 -0.25 (-0.66 to 0.15) .22
Cumulative HAART use,
per 1 year
0.18 (-0.18 to 0.53) .33 0.06 (-0.28 to 0.40) .72 -0.03 (-0.29 to 0.23) .82
Nadir CD4+ T cell count,
per 100 cells/mm3
-0.20 (-0.74 to 0.35) .47 -0.19 (-0.71 to 0.33) .48 -0.22 (-0.61 to 0.18) .28
Cumulative PI use, per 1 year 0.11 (-0.21 to 0.42) .51 0.17 (-0.13 to 0.47) .27 0.09 (-0.14 to 0.32) .42
AIDS diagnosis -2.23 (-6.99 to 2.52) .36 1.56 (-3.01 to 6.12) .50 0.08 (-3.36 to 3.52) .96
VL, viral load.
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the largest cohort to demonstrate this finding. Mansoor et al.
demonstrated an association between increased echocardio-
graphic LVM and HIV infection in women in the Women’s
Interagency Health Study.11 Similarly, Hsue et al., found
greater LVM in HIV-infected persons compared with unin-
fected individuals using echocardiography and greater dia-
stolic dysfunction in conjunction with increased LVM.22
Lipshultz found this association to hold true for children.23
These findings, in total, support the notion that HIVAC in the
era of HAART is characterized by diastolic dysfunction, and
that increased LVM may be underlying this observed clinical
outcome.
Interestingly, none of the HIV clinical factors evaluated was
associated with LVM. Neither degree of control of the virus
(nadir and current CD4+T cell count, detectable viral load, and
history of clinical AIDS) nor antiretroviral use (cumulative
HAART use and cumulative PI use) was associated with LVM
(Table 5). Our inability to identify an HIV clinical factor re-
lated to LVM may due to the power of the study or to a rela-
tively homogenous study population (with regard to control of
HIV and HAART use). Alternatively, the lack of association
between LVM and HIV clinical factors in our study may in-
dicate that the effects of long-term HIV infection on LVM are
unrelated to the level of HIV control achieved or the medica-
tions used to achieve control. The present study excluded
subjects with chronic kidney disease (estimated glomerular
filtration rate <60 mL/min/m2 within 30 days of the CT scan).
As chronic kidney disease (CKD) is known to correlate posi-
tively with LVM24 as well as HIV infection,25 examination of
CKD as a possible covariate represents a potential avenue for
future research. Future research areas could also include ex-
amining the effect of coinfections, opportunistic infections,
and other individual HAART agents on LVM in PLWH.
The other cardiac parameters measured, LVEDV and LAV,
did not differ between the HIV+ and HIV- men. HIV has been
implicated as a risk factor for atrial fibrillation.26 In this cohort,
LAV was similar between HIV+ and HIV- men, suggesting
that any increase in atrial fibrillation incidence in HIV popu-
lations is unrelated to increased chamber size and is perhaps due
to the infiltrative properties of virus or a treatment side effect.
Our study has several limitations. There were differences
in characteristics between HIV+ and HIV- men; however,
hypertension, the strongest predictor of increased LVM, was
similar between the two groups. Importantly, all measured
cardiac risk factors were controlled for in the multivariable
analyses. In addition, the cohort included men only, which
limits generalizability to women. Of note, however, Mansoor
also demonstrated an association between HIV and increased
LVM in a study only including women enrolled in the Wo-
men’s Interagency Health Study.11
The main result of the current investigation is the positive
association between HIV infection and increased LVM. This
finding has important implications in understanding the current
manifestation of HIVAC and in the care of patients with HIV.
Further research using the MACS CVD cohort will include
change in cardiac structure over time and possibly clinical out-
comes (such as heart failure, coronary events) in this population.
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